Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

Ariadna Colomer-Carbonell, Juan P Sanabria-Mazo, Halbert Hernández-Negrín, Xavier Borràs, Carlos Suso-Ribera, Azucena García-Palacios, Jordi Muchart, Josep Munuera, Francesco D'Amico, Michael Maes, Jarred W Younger, Albert Feliu-Soler, Antoni Rozadilla-Sacanell, Juan V Luciano

Research output: Contribution to journalArticleResearchpeer-review

Fingerprint

Dive into the research topics of 'Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)'. Together they form a unique fingerprint.

Nursing and Health Professions

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology

Psychology